Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.

doi:10.1200/JCO.23.02044

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Oct 2024

Yao Herui, Yan Min, Tong Zhongsheng, Wu Xinhong, Ryu Min-Hee, Park John J, Kim Jee Hyun, Zhong Yahua, Zhao Yiming, Voskoboynik Mark, Yin Yongmei, Liu Kan, Kaubisch Andreas, Liu Caigang, Zhang Jian, Wang Shouman, Im Seock-Ah, Ganju Vinod, Barve Minal, Li Hui, Ye Changsheng, Roy Amitesh C, Bai Li-Yuan, Yen Chia-Jui, Gu Shanzhi, Lin Yung-Chang, Wu Lingying, Bao Lequn, Zhao Kaijing, Shen Yu, Rong Shangyi, Zhu Xiaoyu, Song Erwei

Abstract excerpt

PURPOSE: SHR-A1811 is an antibody-drug conjugate composed of an anti-human epidermal growth factor receptor 2 (HER2) antibody trastuzumab, a cleavable linker, and a topoisomerase I inhibitor payload. We assessed the safety, tolerability, antitumor activity, and pharmacokinetics of SHR-A1811 in heavily pretreated HER2-expressing or mutated advanced solid tumors. METHODS: This global, multi-center, first-in-human,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antineoplastic Agents, Immunological

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Immunoconjugates

Share to Maximum Tolerated Dose

Share to Neoplasms

Share to Trastuzumab

Source

Open in PubMed

Identifiers

PMID: 38900984
DOI: 10.1200/JCO.23.02044

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.PMID 38900984Read ↗

SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study.Semantic proximity Read ↗

A First-in-human Phase I Study of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Patients With Advanced Solid Tumors With HER2 or HER3 Aberrations.Semantic proximity Read ↗

Clinical Potential of Antibody–Drug Conjugates in Early-Phase Clinical Trials for Late-Line Treatment of Advanced Solid TumorsSemantic proximity Read ↗

Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Se-Quencing, and SafetySemantic proximity Read ↗

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].Semantic proximity Read ↗

Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.Semantic proximity Read ↗

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.Semantic proximity Read ↗

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read ↗

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.Semantic proximity Read ↗

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.Semantic proximity Read ↗

Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.Semantic proximity Read ↗

Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.